Canada markets open in 6 hours 34 minutes
  • S&P/TSX

    19,361.88
    -110.82 (-0.57%)
     
  • S&P 500

    4,188.43
    -44.17 (-1.04%)
     
  • DOW

    34,742.82
    -34.98 (-0.10%)
     
  • CAD/USD

    0.8264
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    64.49
    -0.43 (-0.66%)
     
  • BTC-CAD

    67,421.75
    -4,252.34 (-5.93%)
     
  • CMC Crypto 200

    1,475.34
    -85.96 (-5.51%)
     
  • GOLD FUTURES

    1,835.30
    -2.30 (-0.13%)
     
  • RUSSELL 2000

    2,212.70
    -58.93 (-2.59%)
     
  • 10-Yr Bond

    1.6020
    0.0000 (0.00%)
     
  • NASDAQ futures

    13,262.75
    -94.00 (-0.70%)
     
  • VOLATILITY

    19.66
    +2.97 (+17.80%)
     
  • FTSE

    7,123.68
    -6.03 (-0.08%)
     
  • NIKKEI 225

    28,608.59
    -909.71 (-3.08%)
     
  • CAD/EUR

    0.6805
    -0.0002 (-0.03%)
     

FibroGen Investor Alert

  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their Options

New York, New York--(Newsfile Corp. - April 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN).

If you suffered losses exceeding $50,000 investing in FibroGen stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/FGEN.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.

On April 6, 2021, after the market closed, FibroGen issued a statement admitting that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to the stratification factors. Specifically, the Company stated: "As members of senior management were preparing for the upcoming FDA Advisory Committee meeting, we became aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors… we promptly decided to clarify this issue with the FDA and communicate with the scientific and investment communities."

On this news, the Company's share price fell as much as 38% in intra-day trading on April 7, 2021, thereby injuring investors.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80498